Local Adjuvant Adoptive Immunotherapy of Patients with Malignant Gliomas
During the past years immunotherapy of patients with malignant brain tumors using biological response modifiers (BRM) such as interferons and interleukin-2 has become an area of increasing interest. The current therapeutic concept consists primarily of surgery which is supported by adjuvant modalities such as radiation therapy and/or chemotherapy. Knowing that the brain is an “immunoprivileged” organ, it would be favorable to modulate the natural immunity in such a way as to rebuild the immune surveillance.
KeywordsMalignant Glioma Brain Edema Glioblastoma Multiforme Malignant Brain Tumor Biological Response Modifier
Unable to display preview. Download preview PDF.
- 6.Yoshida S, Tanaka R, Tahai N, Ono K (1990) Adoptice immunotherapy with LAK cells and interleukin-2 in treatment of recurrent malignant gliomas. Current Therapeutic Research 47:654–664Google Scholar